Pure Global
NCT06039683

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

AstraZeneca·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carcinoma, Non-Small-Cell Lung
Study type
Observational
Sponsor & location
Primary sponsor
AstraZeneca
Location
Kuwait,Doha,Dammam,Jeddah,Riyadh,abu Dhabi,Al Ain,Dubai, Kuwait,Qatar,Saudi Arabia,United Arab Emirates
Timeline & enrollment
Phase
N/A
Start date
Dec 31, 2022
End date
Jun 30, 2024
Enrollment
266 participants
Primary outcome

To describe treatments and sequencing after treatment with first line Osimertinib.,To describe real world time to the next treatment or death (rwTTNTD).

Summary

A Multicountry, Multicenter, Non-interventional, Retrospective Study to determine Real-world
 treatment patterns and associated outcomes after FIRST LINE Osimertinib in patients with
 advanced and Metastatic NSCLC harboring EGFR-activating mutations in the GCC Region

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06039683
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06039683 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 266 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.